EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Glucagon-like peptide-1 receptor agonism improves lung cancer outcomes and tumor growth control

Akhil Goud Pachimatla, Bailey Fitzgerald, Joyce Ogidigo, Meera Bhatia, Randall J Smith, Kalyan Ratnakaram, Sukumar Kalvapudi, Yeshwanth Vedire, Deschana Washington, Robert Vethanayagam Rr, Hua-Hsin Hsiao, Spencer Rosario und 3 weitere

JCI Insight · 2025

DOI: 10.1172/jci.insight.195484 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCI Insight, 2025. Verfasst von Akhil Goud Pachimatla und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, New York, USA. Hauptthemen laut MEDLINE: Lung Neoplasms, Glucagon-Like Peptide-1 Receptor Agonists, Carcinoma, Non-Small-Cell Lung, Obesity. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, Roswell Park Alliance Foundation, Roswell Park Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND. Emerging evidence indicates a reduced incidence of multiple cancers in users of glucagon-like peptide-1 receptor agonists (GLP-1RAs), drugs widely used for glycemic control and weight reduction that modulate several key regulators of metabolism. We sought to examine their association with non–small cell lung cancer (NSCLC) outcomes in overweight and obese patients and gain mechanistic insights from mouse models. METHODS. Two clinical cohorts of overweight and obese patients with NSCLC — one undergoing surgical resection ( n = 1,177, 71 GLP-1RA users) and another receiving immune checkpoint inhibitors ( n = 300, 10 GLP-1RA users), were propensity score matched for relevant covariates and analyzed for clinical outcomes. RESULTS. GLP-1RA use was associated with increased recurrence-free survival in overweight and obese patients (HR: 0.41, 95% CI: 0.16–1.04, P = 0.026) after lobectomy. GLP-1RA treatment reduced tumor burden in obese but not normal-weight mice and altered the frequency and phenotypes of leukocyte populations and gene expression patterns in obese tumors, crucial to cancer progression and antitumor immunity. Concurrent GLP-1RA and immunotherapy was also associated with improved overall (HR: 0.41, 95% CI: 0.16–1.01, P = 0.027) and progression-free survival (HR: 0.31, 95% CI: 0.10–0.94, P = 0.019) for patients with advanced NSCLC. CONCLUSIONS. In our cohort, GLP-1RAs enhanced lung cancer–specific clinical outcomes and augment immunotherapy efficacy. Preclinical evidence suggested this effect to be obesity restricted and mediated by immune modulation of the tumor microenvironment. FUNDING. George Duke, Department of Defense (W81XWH-21-1-0377), NIH/NIGMS (GM147497), American Cancer Society (RSG-22-071-01-TBE), NIH (1R01 CA255515-01A1), NIH/NCI (P30CA013696 and P30CA016056).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsGlucagon-Like Peptide-1 Receptor AgonistsCarcinoma, Non-Small-Cell LungObesityHumansAnimalsMiceFemaleMaleMiddle AgedAgedGlucagon-Like Peptide-1 ReceptorImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

Clinical ResearchDrug therapyLung cancerObesityOncology

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-1 ReceptorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, New York, USA.
  • Department of Medical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
  • Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, USA.
  • Department of Immunology, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, New York, USA.
  • Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
  • Naomi Berrie Diabetes Research Center, Columbia University Irving Medical Center, New York, New York, USA.

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • Roswell Park Alliance Foundation, Roswell Park Cancer Institute
  • Columbia University, Herbert Irving Comprehensive Cancer Center, NIH/NCI Cancer Center Support Grant
  • Roswell Park Comprehensive Cancer Center, NIH/NCI Cancer Center Support Grant

Zitieren

APA

Pachimatla, A. G., Fitzgerald, B., Ogidigo, J., Bhatia, M., Smith, R. J., Ratnakaram, K., Kalvapudi, S., Vedire, Y., Washington, D., Vethanayagam Rr, R., Hsiao, H. H., Rosario, S., Sanghvi, V. R., Barbi, J., & Yendamuri, S. (2025). Glucagon-like peptide-1 receptor agonism improves lung cancer outcomes and tumor growth control. JCI Insight. https://doi.org/10.1172/jci.insight.195484

Vancouver

Pachimatla AG, Fitzgerald B, Ogidigo J, Bhatia M, Smith RJ, Ratnakaram K, et al. Glucagon-like peptide-1 receptor agonism improves lung cancer outcomes and tumor growth control. JCI Insight. 2025. doi:10.1172/jci.insight.195484

BibTeX
@article{Pachimatla2025,
  author = {Pachimatla, Akhil Goud and Fitzgerald, Bailey and Ogidigo, Joyce and Bhatia, Meera and Smith, Randall J and Ratnakaram, Kalyan and Kalvapudi, Sukumar and Vedire, Yeshwanth and Washington, Deschana and Vethanayagam Rr, Robert and Hsiao, Hua-Hsin and Rosario, Spencer and Sanghvi, Viraj R and Barbi, Joseph and Yendamuri, Sai},
  title = {Glucagon-like peptide-1 receptor agonism improves lung cancer outcomes and tumor growth control},
  journal = {JCI Insight},
  year = {2025},
  doi = {10.1172/jci.insight.195484}
}
Kostenlos starten →